Preclinical studies have suggested the synergistic effect of epigenetic modulators and immunotherapy. Here the authors report the results of a phase Ib/II trial of durvalumab and guadecitabine in advanced clear cell renal cell carcinoma.
All Keywords
【저자키워드】 Drug development, renal cell carcinoma, oncology,
【저자키워드】 Drug development, renal cell carcinoma, oncology,